枫蓼肠胃康口服液联合铝碳酸镁治疗慢性胃炎的临床研究

Clinical study on Fengliao Changweikang Oral Liquid combined with hydrotalcite in treatment of chronic gastritis

目的探讨枫蓼肠胃康口服液联合铝碳酸镁片治疗慢性胃炎的临床疗效。方法选取2016年12月-2017年12月内江市第一人民医院收治的100例慢性胃炎患者作为研究对象,将所有患者随机分为对照组(48例)和治疗组(52例)。对照组患者口服铝碳酸镁片,1 g/次,3次/d。治疗组患者在对照组基础上口服枫蓼肠胃康口服液,1支/次,3次/d。两组患者均连续治疗30 d。观察两组患者的临床疗效,同时比较两组治疗前后的红细胞免疫功能指标、胃肠激素水平、血清细胞因子水平和胃肠道功能评分。结果治疗后,对照组和治疗组的总有效率分别为75.00%、92.31%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组红细胞受体C3b花环活性率(RBC-C3bRR)、红细胞免疫黏附促进因子(RFER)均显著升高,红细胞免疫复合物花环(RBC-ICR)、红细胞抑制因子(RFIF)显著降低(P<0.05);治疗组红细胞免疫功能指标显著优于对照组(P<0.05)。治疗后,两组患者的胃泌素、生长抑素、胃蛋白酶原水平均显著升高(P<0.05);治疗组胃肠激素水平显著高于对照组(P<0.05)。治疗后,两组γ-干扰素(IFN-γ)、白细胞介素-17A(IL-17A)水平均显著升高,白细胞介素-4(IL-4)、转化生长因子-β(TGF-β)显著降低(P<0.05);治疗组血清细胞因子水平显著优于对照组(P<0.05)。治疗后,两组一氧化氮(NO)水平显著升高,表皮生长因子(EGF)、白细胞介素-32(IL-32)均显著降低(P<0.05);治疗组血清学指标显著优于对照组(P<0.05)。治疗后,两组GSRS-C评分显著降低(P<0.05);治疗后,治疗组GSRS-C评分显著低于对照组(P<0.05)。结论枫蓼肠胃康口服液联合铝碳酸镁片治疗慢性胃炎具有较好的临床疗效,能有效改善患者胃功能,降低其炎性损伤程度,具有一定的临床推广应用价值。

Objective To investigate the clinical efficiency of Fengliao Changweikang Oral Liquid combined with Hydrotalcite Tablets in treatment of chronic gastritis. Methods Patients(100 cases) with chronic gastritis in The First People’s Hospital of Neijiang from December 2016 to December 2017 were randomly divided into the control group(48 cases) and treatment group(52 cases). Patients in the control group were po administered with Hydrotalcite Tablets, 1 g/time, three times daily. Patients in the treatment group were po administered with Fengliao Changweikang Oral Liquid on the basis of control group, 1 tube/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the erythrocyte immune function indexes, gastrointestinal hormone levels, serum cytokines levels, and GSRS-C scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 75.00% and 92.31%, respectively, and there were differences between two groups(P < 0.05). After treatment, RBC-C3 bRR and RFER in two groups were significantly increased, but RBC-ICR and RFIF were significantly decreased(P < 0.05). After treatment, erythrocyte immune function indexes in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the levels of gastrin, somatostatin, and pepsinogen in two groups were significantly increased(P < 0.05). After treatment, the levels of gastrointestinal hormone in the treatment group were significantly higher than those in the control group(P < 0.05). After treatment, IFN-γ and IL-17 A in two groups were significantly increased, but IL-4 and TGF-β were significantly decreased(P < 0.05). After treatment, serum cytokines levels in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, NO levels in two groups were significantly increased, but EGF and IL-32 levels were significantly decreased(P < 0.05). After treatment, serological indicators in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the GSRS-C scores in two groups were significantly decreased(P < 0.05). After treatment, the GSRS-C scores in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Fengliao Changweikang Oral Liquid combined with Hydrotalcite Tablets has a good effect in treatment of chronic gastritis, can effectively improve the gastric function of patients, and reduce the degree of inflammatory injury, which has a certain clinical application value.